Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Current Opinion in Lipidology
|
February 2, 2018
Familial hypercholesterolemia: experience from France
Jean-Pierre Rabès, Sophie Béliard, Alain Carrié
Atherosclerosis
|
May 31, 2021
APOE gene variants in primary dyslipidemia
Yara Abou Khalil, Jean-Pierre Rabès, Catherine Boileau, et al.
International Journal of Molecular Sciences
|
January 10, 2026
A Simple Restriction Fragment Length Polymorphism-Based Method for Multiplex Testing of Thrombosis Risk Factors FV Leiden and <i>F2</i> G20210A with Highly Sensitive Contamination Detection
Philippe de Mazancourt, Sylvie Grey, Elise Alabre, et al.
Frontiers in Cardiovascular Medicine
|
August 4, 2023
Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
Anthony Matta, Jean Pierre Rabès, Dorota Taraszkiewicz, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
May 7, 2021
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta, Vanina Bongard, Frédéric Bouisset, et al.
Clinical Cardiology
|
March 26, 2018
Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk
Florent Séguro, Jean-Pierre Rabès, Dorota Taraszkiewicz, et al.
Presse Medicale (Paris, France : 1983)
|
August 1, 2018
[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians]
Sophie Béliard, Jean-Pierre Rabès, Bertrand Cariou, et al.
Human Mutation
|
February 5, 2009
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
Marianne Abifadel, Jean-Pierre Rabès, Martine Devillers, et al.
Expert Opinion on Therapeutic Patents
|
September 21, 2010
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Marianne Abifadel, Jihane Pakradouni, Matthieu Collin, et al.
Expert Opinion on Therapeutic Patents
|
July 1, 2016
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
Sandy Elbitar, Petra El Khoury, Youmna Ghaleb, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Current Opinion in Lipidology
|
February 2, 2018
Familial hypercholesterolemia: experience from France
Jean-Pierre Rabès, Sophie Béliard, Alain Carrié
Atherosclerosis
|
May 31, 2021
APOE gene variants in primary dyslipidemia
Yara Abou Khalil, Jean-Pierre Rabès, Catherine Boileau, et al.
International Journal of Molecular Sciences
|
January 10, 2026
A Simple Restriction Fragment Length Polymorphism-Based Method for Multiplex Testing of Thrombosis Risk Factors FV Leiden and <i>F2</i> G20210A with Highly Sensitive Contamination Detection
Philippe de Mazancourt, Sylvie Grey, Elise Alabre, et al.
Frontiers in Cardiovascular Medicine
|
August 4, 2023
Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
Anthony Matta, Jean Pierre Rabès, Dorota Taraszkiewicz, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
May 7, 2021
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
Anthony Matta, Vanina Bongard, Frédéric Bouisset, et al.
Clinical Cardiology
|
March 26, 2018
Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk
Florent Séguro, Jean-Pierre Rabès, Dorota Taraszkiewicz, et al.
Presse Medicale (Paris, France : 1983)
|
August 1, 2018
[Familial hypercholesterolemia: An under-diagnosed and under-treated disease. Survey of 495 physicians]
Sophie Béliard, Jean-Pierre Rabès, Bertrand Cariou, et al.
Human Mutation
|
February 5, 2009
Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
Marianne Abifadel, Jean-Pierre Rabès, Martine Devillers, et al.
Expert Opinion on Therapeutic Patents
|
September 21, 2010
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Marianne Abifadel, Jihane Pakradouni, Matthieu Collin, et al.
Expert Opinion on Therapeutic Patents
|
July 1, 2016
Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015)
Sandy Elbitar, Petra El Khoury, Youmna Ghaleb, et al.
Page
of 5